Clinical trials are the backbone of innovation in cancer treatment. They offer hope to patients and families, serve as a gateway to groundbreaking therapies, and provide clinicians with new tools to improve outcomes. In the era of precision oncology, where genomic insights shape treatment strategies, clinical trials are more critical than ever. However, despite their importance, accessing the right trial often presents challenges, especially when matching specific genetic profiles to available options.
At Genomenon, we are addressing these challenges head-on. With the recent expansion of our Cancer Knowledgebase (CKB), we have incorporated clinical trial data from 25 additional European countries. This enhancement brings our global coverage to 39 countries, making it easier than ever for clinicians to connect their patients to trials that are geographically accessible and genomically relevant. This is more than a technical update—it’s a significant step toward democratizing access to life-changing cancer treatments.
The Role of Clinical Trials in Transforming Cancer Care
Clinical trials play a pivotal role in advancing cancer research and care. They act as the bridge between scientific discovery and real-world application, providing patients with access to therapies that can be more effective than standard treatments. For clinicians, trials offer an essential option, especially when conventional treatments are not effective. For researchers, they are a source of invaluable data, driving innovation and shaping the future of oncology.
What sets clinical trials apart in precision medicine is their focus on matching therapies to the unique genetic makeup of a patient’s cancer. This approach has the potential to transform outcomes, offering treatments that are specifically designed to target the molecular drivers of disease. However, identifying the right trial for a patient’s genetic profile can be a complex and time-consuming process—a challenge that CKB is designed to solve.
How CKB Enhances Access to Clinical Trials
The Cancer Knowledgebase is a trusted resource used by thousands of clinicians and researchers worldwide. It simplifies the process of interpreting complex cancer genomic profiles and provides actionable insights into the relationships between cancer variants, therapies, and clinical trials. With the addition of clinical trials from 25 European countries, CKB has significantly enhanced its ability to connect patients with appropriate treatment options.
This expansion ensures that clinicians and researchers can easily access trial data relevant to their patients, regardless of location. By integrating this information with CKB’s genomic intelligence, we empower users to identify trials tailored to the specific needs of their patients. This development has the potential to improve outcomes, particularly for patients in regions where access to cutting-edge therapies has been limited.
A Flexible Resource for Clinicians and Researchers
CKB is designed to meet the diverse needs of its users through multiple access options. CKB CORE offers free access to curated data on 50 cancer-related genes, providing an entry point for users to explore its capabilities. For those requiring more extensive insights, CKB BOOST delivers data on over 2,000 cancer-related genes via a web-based interface. Additionally, CKB FLEX offers downloadable content in flat files or JSON, enabling seamless integration into research workflows.
These options ensure that whether you are a clinician seeking immediate answers for a patient’s case or a researcher exploring the latest in cancer genomics, CKB is a flexible and invaluable tool. With regular updates and an ever-expanding dataset, it is built to keep pace with the rapidly evolving landscape of cancer research and care.
Shaping the Future of Precision Medicine
The expansion of CKB’s clinical trial coverage is a testament to our commitment to advancing precision medicine. By bridging the gap between genomic data and clinical application, CKB helps clinicians and researchers translate complex information into actionable insights. This not only improves patient care but also accelerates the pace of discovery in oncology.
At Genomenon, we believe that every cancer patient deserves access to the best possible treatments, and we are dedicated to making this a reality. With this latest enhancement to CKB, we are proud to support the global oncology community in its mission to improve outcomes and transform lives.
Upgrade to CKB BOOST to explore global clinical trials and find precise, targeted treatment options for your patients.
